Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yuka Ito

A Randomized, Placebo- And Sitagliptin-Controlled Trial of the Safety and Efficacy of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Japanese Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Local Land Subsidence Exacerbates Inundation Hazard to the Kujukuri Plain, Japan

Proceedings of the International Association of Hydrological Sciences
EarthPlanetary Sciences
2020English

Related publications

Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients With Type 2 Diabetes: The EDIT Randomized Trial

PLoS ONE
Multidisciplinary
2015English

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2006English

Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2017English

Efficacy and Safety of Repaglinide Added to Sitagliptin in Japanese Patients With Type 2 Diabetes: A Randomized 24-Week Open-Label Clinical Trial

Endocrine Journal
EndocrinologyMetabolismDiabetes
2016English

Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Hydroxychloroquine in Patients With Type 2 Diabetes Mellitus

Global Journal of Endocrinological Metabolism
2018English

Combination Therapy With Once-Weekly Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Case Series

Pharmacy Practice
Pharmaceutical SciencePharmacy
2019English

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology
Pharmacology
2018English

Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy